Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Spectral DNC-N® significantly reduced hair shedding and increased hair mass and density in women with early female pattern hair loss, with effects evident after 3 months and sustained through 6 months.

This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.

This study reported that the tested hair lotion significantly reduced hair loss and accelerated recovery in women with acute telogen effluvium compared to a mild shampoo alone.

In this study, nanostructured lipid carriers for hair split-end repair showed similar efficacy regardless of charge, with negatively charged carriers exhibiting better stability over six months compared to positively charged ones.

This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.

In this study, a new leave-on hair treatment with Dynagen and zinc salts significantly increased hair growth rate, fibre diameter, and follicle strength in healthy women.

This study found that taking a daily oral dose of 50mg DHEA for one year had no significant impact on blood lipids, insulin sensitivity, or the endometrium in postmenopausal women with low libido.

This review summarizes the potential of nanostructured lipid carriers in drug delivery systems, highlighting their promise in enhancing the stability and skin penetration of anti-aging cosmetics.

This study found that diode laser reduced axillary hair more effectively but with greater pain than intense pulsed light, with both methods producing lasting and safe results.

This study found that nanostructured lipid carriers could serve as a promising vehicle for topical Acitretin delivery in psoriasis treatment, potentially reducing oral side effects and enhancing patient compliance.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.

The laser therapy device effectively increased hair growth in people with androgenetic alopecia.

In this study, researchers reported that topical nanostructured lipid carriers containing tea seed or lavender oil significantly enhanced hair regrowth in female Wistar albino rats over 30 days compared to placebo, with increased hair length and follicular density observed.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.

In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.

Two lotions used day and night may be a good alternative to minoxidil for hair loss, with better cosmetic effects and tolerance.

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

This study found that the topical application of DA-OTC-002, a combination of synephrine and tyramine hydrochloride, significantly reduced immediate hair shedding in women by 62.5% compared to a placebo, without any observed adverse effects.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

This study reported the successful development of finasteride-loaded poly(lactic-co-glycolic acid) nanoparticles, with varying encapsulation efficiencies, aiming to enhance drug delivery for hair growth while minimizing side effects, and noted that an in vivo study will follow to assess efficacy.

In this study, low-dose spironolactone reduced the severity of female pattern hair loss in a small group of women without causing significant side effects, suggesting it may be an effective and well-tolerated treatment option.

The lotion helps manage mild to moderate hair loss.

This study reviewed the pharmacological properties of Priyaladi lepa, an Ayurvedic formulation, and reported its potential anti-dandruff benefits due to anti-inflammatory, anti-fungal, anti-microbial, anti-pruritic, antioxidant, and exfoliation effects, warranting further research for managing Darunaka (dandruff).